← back to search

Jason R.B. Dyck

University of Alberta · CA
Area of research
Cardiology and Cardiovascular Medicine · Physiology
Research interest
Research interests include Cardiovascular Function and Risk Factors, Adipose Tissue and Metabolism, Metabolism, Diabetes, and Cancer, and Sirtuins and Resveratrol in Medicine.
h-index
91
citations
27,747
works
417
NIH funding
primary concept
Medicine
email

Recent publications

Risk of Heart Failure-related Events in Patients Exposed to Medical Cannabis: A Longitudinal Cohort Study
American Journal of Medicine Open 2026cited by 1position: contributordoi
Ketone therapy prevents semaglutide-induced loss of cardiac mass.
2026cited by 0position: contributordoi
Sex-specific effects of abdominal aortic constriction on renal cytochrome P450 enzymes and arachidonic acid metabolites in male and female rats.
2026cited by 0position: contributordoi
Opioid Initiation in Older Patients with Chronic Pain Who Received Authorized Cannabis Prescription.
2026cited by 0position: contributordoi
Therapeutic potential of ketone bodies on exercise intolerance in heart failure: looking beyond the heart.
2025cited by 4position: contributordoi
Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.
2025cited by 0position: contributordoi
Lowering Cardiac Branched-Chain Keto Acid Levels Enhances Cardiac Glucose Oxidation and Cardiac Efficiency via Enhancing Mitochondrial Insulin Signaling in Heart Failure.
2025cited by 0position: contributordoi
Reply
JACC: Basic to Translational Science 2025cited by 0position: contributordoi
Remembering Dr Gary D. Lopaschuk, PhD (1956–2025)
Cardiovascular Research 2025cited by 0position: contributordoi
Sodium-glucose cotransporter 2 Inhibitors and COVID-19 outcomes in type 2 diabetes patients: A population-based cohort study
Diabetes Epidemiology and Management 2025cited by 0position: contributordoi
The therapeutic potential of ketones in cardiometabolic disease: impact on heart and skeletal muscle.
2024cited by 18position: contributordoi
Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice
JACC: Basic to Translational Science 2024cited by 14position: contributordoi
Pharmacological Inhibition of Succinyl Coenzyme A:3-Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy.
2024cited by 6position: contributordoi
Cannabidiol Suppresses Cytokine Storm and Protects Against Cardiac and Renal Injury Associated with Sepsis.
2024cited by 4position: contributordoi
Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?
2024cited by 0position: contributordoi
Exogenous ketone therapy does not protect brain tissue after moderate-sized intracerebral hemorrhage despite signs of early neurological benefit.
2024cited by 0position: contributordoi
Ketones and the cardiovascular system.
2023cited by 53position: contributordoi
Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
2023cited by 53position: contributordoi
Development and validation of echocardiography-based machine-learning models to predict mortality
EBioMedicine 2023cited by 32position: middledoi
Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation.
2023cited by 11position: contributordoi
Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study
Psychiatry Research 2023cited by 6position: contributordoi
Ketone therapy for heart failure: current evidence for clinical use.
2022cited by 39position: contributordoi
Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.
2022cited by 5position: contributordoi
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Circulation 2021cited by 183position: contributordoi
Empagliflozin suppresses inflammation and protects against acute septic renal injury.
2021cited by 60position: contributordoi
Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice.
2021cited by 42position: contributordoi
The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.
2021cited by 39position: contributordoi
Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart.
2021cited by 35position: contributordoi
Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation.
2021cited by 27position: contributordoi
Cardiac remodelling predicts outcome in patients with chronic heart failure.
2021cited by 16position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 33 papers (2020–2026)Martin E. Young · University of Alabama at Birmingham9 papers (2012–2020)John Ussher · Mahindra and Mahindra Limited (India)8 papers (2019–2025)Dean T. Eurich · University of Alberta6 papers (2020–2026) · 6 papers (2013–2016) · 5 papers (2021–2025)Gavin Y. Oudit · University of Alberta5 papers (2015–2021)Thomas Pulinilkunnil · McMaster University5 papers (2013–2013)Jeevan Nagendran · McMaster University5 papers (2012–2013)Mark J. Haykowsky · St Vincents Institute of Medical Research5 papers (2013–2021)Cerina Dubois · International Scientific Information, Inc.4 papers (2025–2026)Arsene Zongo · Robert Koch Institute4 papers (2023–2026)Jonathan G Howlett · Calgary Laboratory Services4 papers (2019–2021)Justin A. Ezekowitz · Canadian VIGOUR Centre4 papers (2019–2023)Beshay N. Zordoky · McMaster University4 papers (2013–2015)Petra C. Kienesberger · McMaster University4 papers (2013–2013)Nikole J. Byrne · Medical University of Graz3 papers (2016–2020)Shingo Takahara · Tohoku University3 papers (2021–2022) · 3 papers (2020–2021)Gary D. Lopaschuk · EMBO Molecular Medicine3 papers (2023–2025)